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Dear Editor,
I read with interest the work of Mott et al., published in 
Applied Health Economics and Health Policy in 2020 [1]. In 
this publication, the authors conclude that “Patients in dif-
ferent European countries do not have the same preferences 
for the attributes of diagnostic tests to manage antimicrobial 
resistance (AMR) in primary care.”
In this respect, and in respect to the comment “Consider-
ing patient preferences when designing diagnostic tests is 
important because individuals’ preferences could directly 
influence their uptake of such tests, yet to date no studies 
have explored this issue.”, I would like to draw the authors’ 
attention to an article published on a related theme from 
2013, namely “Perceptions of point-of-care infectious dis-
ease testing among European medical personnel, point-
of-care test kit manufacturers, and the general public” [2], 
which was part of a European Union (EU)-funded FP7 pro-
ject (TEMPOtest-QC—Grant agreement ID 241742) [3]. I 
would also like to draw on my own (albeit non-economics-
based) experience in this area [4–7].
Point-of-Care Although not mentioned, I think that the 
article by Mott et al. should perhaps have specifically used 
the term ‘Point-of-Care’ or ‘Point-of-Need’ (POC) diag-
nostics, as the research performed is focussed on individu-
als that had been patients prescribed antibiotics within the 
last 2 years (“Medical professionals were excluded from 
participating.”), and this focal group may seldom have a say 
in the choice of diagnostic that is to be used to treat them. An 
exception to this assertion is POC testing, where the patient 
privately purchases their own diagnostic test and therefore 
actively contributes to the diagnostic purchasing process. 
Therefore, I would suggest that the statement “Patient prefer-
ences are important in determining whether diagnostic tests 
are successful in practice” may have little relevance outside 
of POC testing (see also ‘Expectations’).
Expectations The authors write “Patient perceptions are 
important when it comes to the use and misuse of antibiot-
ics as the overuse of antibiotics is shaped significantly by 
physicians’ desire to satisfy patient demand. It has been 
illustrated that parental expectations around antimicrobial 
prescribing drives clinicians’ prescription behaviour, and it 
has been suggested that joint physician-patient (or physician-
carer) level decision making needs to be addressed in order 
to tackle the misuse of antibiotics.” Basically, the first state-
ment relates to certain patients demanding antibiotics from 
physicians without sufficient evidence to support their actual 
prescription. I am not convinced that talking with patients, 
or offering them a diagnostic test, is a feasible option here. 
This opinion is based on the time constraints involved in the 
doctor–patient consult and the possible extra costs incurred 
in performing a diagnostic test (which in any case may not 
actually change the patient’s mind). A better option perhaps 
would be to offer the patients a tangible alternative ‘therapy’, 
but not antibiotics. In the article “‘Out-of-the-box’ thinking 
to help stop the spread of antibiotic resistance” [8], I sug-
gested the use of multivitamins as a first-line response to 
patients that insist on receiving a course of antibiotics. This 
would be less time consuming, probably more cost effective 
than using a diagnostic test and, importantly, perhaps better 
appreciated by the patient.
Costs The authors state that “Whilst many studies exam-
ine willingness to pay, cost was not included as an attrib-
ute in the discrete choice experiment (DCE) as it was not 
deemed appropriate in this context (most of the countries 
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studied have largely publicly funded health care systems).”, 
which appears to contradict the focal group of the research; 
that is, individuals that had been patients prescribed antibi-
otics within the last 2 years. In a world ruled by econom-
ics, it would be difficult to justify the use of a diagnostic to 
manage infection if the financial costs of prevention, treat-
ment and disease are not known (this calculation includes 
the healthcare costs associated with primary care physician 
budgets). By omitting medical professionals, it appears that 
the authors necessarily focus on potential end users, that 
is, the group that would be buying and using these kind of 
tests—the patients themselves. Further, private healthcare 
within publicly funded healthcare systems is not forbidden 
and many end users may consider buying ‘off-the-shelf’ or 
‘off-the-internet’ diagnostic tests if they feel that they are not 
receiving the most appropriate care within publicly funded 
healthcare systems. This means that costs are likely to be a 
major factor in the choice of diagnostic by end users, and as 
such most certainly should be considered by manufacturers 
of such diagnostics. From our own research, it appears that 
the price of a (POC) diagnostic is indeed a consideration in 
the potential use of such diagnostics by the general public. 
Importantly, not all members of the general public expect 
to receive free diagnostic testing and would be prepared to 
pay between €5 and €25 (Table 3—2011/2012 prices [2]) for 
a single diagnostic test. The authors state “Additionally, it 
has been shown that inclusion of a cost attribute can affect 
choice behaviour in DCEs, resulting in different relative 
preferences and an increase in error variance.” However, I 
am not sure that this is a valid criterion not to include costs 
in the analysis. Perhaps the limitation lies with the DCE 
analysis as a technique, rather than the choice of ‘cost’ as a 
preference variable?
Confidence One of the key points mentioned by the 
authors is that “confidence in the test result was the most 
important attribute for patients in some countries”. Most 
diagnostics are performed by trained clinicians or nurses, so 
I would be surprised if a patient asks their healthcare worker 
about the healthcare workers’ confidence in the result. How-
ever, I can imagine that if the result goes against patient 
expectations—leading to, for example, a positive HIV result, 
or a decision involving non-prescription of antibiotics—then 
the patient may question the result. Also, whether the health-
care worker has information available regarding a diagnos-
tics (relative) performance (e.g., specificity, sensitivity, etc.) 
is another issue. Finally, even if an answer is provided such 
as “The error rate is 1 in 1000”, patients may still believe 
that they are the 1 out of 1000 patients that has received an 
incorrect result.
In conclusion, Mott et al., have produced a valuable inter-
nationally relevant publication with some important recom-
mendations for AMR diagnostics. However, there appear to 
be some potential caveats in the methodology of the research 
that may influence the general applicability of the findings. 
In any case, we agree that a ‘one size fits all’ approach is 
likely not feasible for (POC) diagnostics designed to help 
combat infectious diseases and (inaccurate/inappropri-
ate) antibiotic prescribing. Additionally, we agree that the 
choices made by end users of infectious disease and AMR 
diagnostics vary (inter)nationally.
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